Chuck Harris, (SCHNON), Director, Product Development, Endpoint Clinical, Inc., United States
Mr. Harris brings 10+ years of IRT (IVR/IWR) experience to his current role managing Product Development for next generation IRT provider Endpoint. He works closely with customers to ensure Endpoint’s IRT solutions revolutionize industry standard IVR/IWR product and service delivery expectations.
SPEAKER
(S):
Chuck Harris, (SCHNON), Director, Product Development, Endpoint Clinical, Inc., United States
Mr. Harris is Director of Operations for United BioSource Corporation's (UBC) Clinical Technologies, which provides technology-driven solutions for clinical trials and investigational supplies management through IVRS/IWRS. Prior to UBC, Mr. Harris held roles in the software industry and with the FDA
Studied ecology and radiation protection. 2002-2008 worked as an R&D associate in molecular biophysics. 2009-2012 works for PAREXEL, Clinical Logistics Services, managing clinical supply activities for global trials. From 2012 involved in development and setup of IT solutions for trial supply
Karen McNamara, MBA (SPKNON), Senior Manager, Clinical Supply, Infinity Pharmaceuticals, Inc., United States
Karen McNamara is a Clinical Supply Manager at Infinity Pharmaceuticals, Inc. where she is responsible for timely preparation and delivery of clinical trial materials for global clinical trials which include activities such as labeling, packaging, distribution, and inventory management.
Description
This symposium will address a number of current clinical supplies topics, including managing the ever-growing costly needs of large-scale investigator-initiated studies (IIS)/investigator-initiated trials (IIT)/investigator-sponsored trials (IST) program management, mitigating risk in your interactive response technology (IRT) system's automated supply chain configuration, and an update on methods for maintaining regulatory compliance with continuously evolving import/export processes. Through a combination of instruction and case studies, our panel will surface recent developments in these areas that impact a broad spectrum of clinical operations stakeholders.